Important Notice for AstraZeneca PLC Shareholders: Securities Fraud Allegations
NEW YORK, Feb. 12, 2025 – The Gross Law Firm, a leading securities fraud class action law firm, notifies investors that a securities fraud class action has been filed against AstraZeneca PLC (NASDAQ: AZN) on behalf of shareholders who purchased or otherwise acquired AstraZeneca securities between January 1, 2020, and November 1, 2024. This class action seeks to recover damages on behalf of AstraZeneca shareholders.
Allegations Against AstraZeneca
The complaint alleges that AstraZeneca and certain of its executives made false and misleading statements and failed to disclose material information regarding the safety and efficacy of its drug, Farxiga, and its combination with other diabetes medications, including Onglyza and Kombiglyze XR. Specifically, the complaint alleges that AstraZeneca failed to disclose that the combination therapy increased the risk of cardiovascular events, including heart failure and death, in certain patients.
Impact on Individual Investors
If you purchased or otherwise acquired AstraZeneca securities during the Class Period and suffered a loss, you may be entitled to compensation. The deadline to seek appointment as lead plaintiff in the AstraZeneca class action is April 12, 2025. To learn more, please contact The Gross Law Firm as soon as possible.
Global Implications
The allegations against AstraZeneca could have significant implications for the pharmaceutical industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other drug companies and their safety and efficacy claims. It could also result in increased regulation and oversight of the pharmaceutical industry, potentially leading to higher costs and lower profits for drug companies.
Conclusion
The securities fraud class action against AstraZeneca PLC is an important development for investors in the pharmaceutical industry. If you purchased or otherwise acquired AstraZeneca securities during the Class Period, you may be entitled to compensation. The deadline to seek appointment as lead plaintiff in the AstraZeneca class action is April 12, 2025. For more information, please contact The Gross Law Firm as soon as possible. This development also highlights the importance of transparency and honesty in the pharmaceutical industry, as well as the need for increased regulation and oversight to protect investors and ensure the safety and efficacy of drugs.
- A securities fraud class action has been filed against AstraZeneca PLC on behalf of shareholders who purchased or otherwise acquired AstraZeneca securities between January 1, 2020, and November 1, 2024.
- The complaint alleges that AstraZeneca and certain executives made false and misleading statements and failed to disclose material information regarding the safety and efficacy of its drug, Farxiga, and its combination with other diabetes medications.
- The allegations against AstraZeneca could have significant implications for the pharmaceutical industry as a whole, potentially leading to increased regulation and oversight and higher costs for drug companies.
- If you purchased or otherwise acquired AstraZeneca securities during the Class Period and suffered a loss, you may be entitled to compensation. The deadline to seek appointment as lead plaintiff in the AstraZeneca class action is April 12, 2025.
